Form 4: Acelyrin CFO and CBO Gil M Labrucherie Acquires 184,042 Employee Stock Options

Gil M Labrucherie, CFO and CBO of Acelyrin, Inc., acquired 184,042 employee stock options on May 23, 2024, at an exercise price of $4.22.

Summary

• On May 23, 2024, Gil M Labrucherie, the CFO and CBO of Acelyrin, Inc. (SLRN), acquired 184,042 employee stock options.
• The exercise price for these options is $4.22.
• The options vest in three tranches: 33% on December 15, 2024, 34% on June 15, 2025, and the remaining 33% on December 15, 2025, contingent upon continued service.
• The expiration date for the options is May 22, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a key executive is generally viewed as a positive sign, indicating confidence in the company's future. However, it's a routine event and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options by a key executive like the CFO and CBO can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Comparing the size and vesting schedule of this grant to similar companies like BioNTech or Moderna would provide a better understanding of its competitiveness.
• The vesting schedule is fairly standard, with vesting occurring over a period of approximately 1.5 years.

Stakeholder Impact

• Shareholders may view this as a positive sign of management alignment with company goals.
• Employees may see this as a positive indicator of the company's commitment to its leadership.

Key Dates